Phase 2a Study of HPG1860 in Subjects With NASH
| 대상 질환 | NASH - Nonalcoholic Steatohepatitis |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Hepagene (Shanghai) Co., Ltd. |
| 상태 | 완료 |
| 참여자 수 | 89 명 |
| 중재(약물) | HPG1860 |
| 시작일 | 2021년 11월 22일 |
| 완료일 | 2023년 2월 28일 |
| 결과 공개일 | 2026년 5월 28일 |
요약
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
Safety and Tolerability of Treatment
| Placebo | 12 Participants |
|---|---|
| HPG1860 3 mg | 13 Participants |
| HPG1860 5 mg | 13 Participants |
| HPG1860 8 mg | 18 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)